OPR - Delayed Quote • USD IBRX Oct 2024 3.500 call (IBRX241018C00003500) Follow 3.0000 +1.4000 (+87.50%) At close: April 26 at 12:01 PM EDT Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw Table View List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Date Close Open High Low Volume O H L C Vol AAPL Loading Chart for IBRX241018C00003500 1D 5D 1M 3M 6M YTD 1Y 2Y 5Y All Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: IBRX ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer ImmunityBio's bladder cancer therapy wins FDA approval ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer NIAID-Sponsored Study Shows N-803 Combined with Neutralizing Antibodies Could Lead to Sustained HIV Viral Control After Discontinuation of Antiretroviral Therapy N-803 Combined with Natural Killer Cells Showed Potential to Reduce HIV Viral Load in HIV Positive Subjects; Part of HIV Cure Study ImmunityBio Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the Trial ImmunityBio, Inc. (NASDAQ:IBRX): When Will It Breakeven? ImmunityBio Quality-of-Life Study in BCG-Unresponsive Bladder Cancer Trial Indicates Improved Physical Function in the 71% Complete Responders Suggesting a Favorable Risk-Benefit Ratio for N-803 Plus BCG ImmunityBio Announces $320 Million Investment by Oberland Capital, with $210 Million Funded at Closing, Bringing Total Financing in 2023 to $850 Million ImmunityBio to Participate in 35th Annual Piper Sandler Healthcare Conference First Data for ImmunityBio’s Memory Cytokine-Enriched NK Cells in Small Cell Lung Cancer at SITC Meeting Show Promising Anti-tumor Activity FDA Accepts ImmunityBio’s BLA Resubmission as Complete and Sets New PDUFA Date
